The estimated Net Worth of Steven Lo is at least $2.21 Million dollars as of 6 June 2022. Mr Lo owns over 442 units of Zosano Pharma Corp stock worth over $7,371 and over the last 14 years he sold ZSAN stock worth over $1,443,599. In addition, he makes $756,275 as Sr. VP of Operations, Pres, and CEO & Director at Zosano Pharma Corp.
Mr has made over 20 trades of the Zosano Pharma Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 442 units of ZSAN stock worth $314 on 6 June 2022.
The largest trade he's ever made was exercising 585,416 units of Zosano Pharma Corp stock on 16 November 2015 worth over $1,797,227. On average, Mr trades about 40,257 units every 63 days since 2010. As of 6 June 2022 he still owns at least 13,163 units of Zosano Pharma Corp stock.
You can see the complete history of Mr Lo stock trades at the bottom of the page.
Steven Lo is the Sr. VP of Operations, Pres, CEO & Director at Zosano Pharma Corp.
As the Sr. VP of Operations, Pres, and CEO & Director of Zosano Pharma Corp, the total compensation of Mr Lo at Zosano Pharma Corp is $756,275. There are no executives at Zosano Pharma Corp getting paid more.
Mr Lo is 54, he's been the Sr. VP of Operations, Pres, and CEO & Director of Zosano Pharma Corp since . There are 3 older and 5 younger executives at Zosano Pharma Corp. The oldest executive at Zosano Pharma Corp is Dr. Donald J. Kellerman, 66, who is the VP of Clinical Devel. & Medical Affairs.
Steven's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L..., and Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: